INIVATA LIMITED – Trademark Portfolio
Entity Type: 11
INIVATA LIMITED holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 11 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 4 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include RADAR, NEORADAR, and INVISIONFIRST-LUNG. The owner is based in BabrahamCambridge.
The Glenn Berge Building,
BabrahamCambridge CB22 3FH , GB
Showing of trademarks Trademarks
Trademark Classifications
INIVATA LIMITED's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does INIVATA LIMITED have?
INIVATA LIMITED has 11 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 cancelled.
What trademark classes does INIVATA LIMITED file in?
INIVATA LIMITED files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 42 covers scientific and technological services; industrial analysis and research services.
What are INIVATA LIMITED's most well-known trademarks?
INIVATA LIMITED's registered trademark portfolio includes well-known marks such as RADAR, NEORADAR, and INVISIONFIRST-LUNG. These are among 3 currently registered trademarks in the portfolio.
What is INIVATA LIMITED's trademark registration success rate?
INIVATA LIMITED has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.